Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals potential growth. Read why RADX stock is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback